scholarly journals Experience in the Surgical Management of Two Cases with Acromegaly

2021 ◽  
Vol 35 (2) ◽  
pp. 35-37
Author(s):  
Eka J. Wahjoepramono
Keyword(s):  
Growth Hormone ◽  
Pituitary Adenoma ◽  
Clinical Presentation ◽  
Radiologic Finding ◽  
Tumor Mass ◽  
Factor I ◽  
Chronic Disorder ◽  
Igf I ◽  
Radiation Treatments

Acromegaly is a chronic disorder that usually develops over many years due to long term exposure to elevated levels of growth hormone (GH) most typically caused by a somatotrophic cell pituitary adenoma. It has an annual incidence of approximately 3-4 cases / million. A diagnosis of acromegaly is made based on the clinical presentation, biochemical and radiologic finding. The classical feature is the change in appearance and acral enlargement. No single therapy is comprehensively successful in controlling the disease. Surgical, medical and radiation treatments are available for lowering GH and insulin-like growth factor I (IGF-I) hypersecretion, controlling pituitary tumor mass effects, and lowering morbidity.

Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment

2006 ◽  
Vol 65 (3) ◽  
pp. 310-319 ◽  
Author(s):  
Ellen M. N. Bannink ◽  
Jaap van Doorn ◽  
Theo Stijnen ◽  
Stenvert L. S. Drop ◽  
Sabine M. P. F. de Muinck Keizer-Schrama
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Turner Syndrome ◽  
Binding Proteins ◽  
Growth Hormone Treatment ◽  
Hormone Treatment ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Igf I

Analyses from a Centre of Short- and Long-Term Growth in Turner’s Syndrome on Standard Growth Hormone Doses Confirm Growth Prediction Algorithms and Show Normal IGF-I Levels

2012 ◽  
Vol 77 (4) ◽  
pp. 214-221 ◽  
Author(s):  
Michael B. Ranke ◽  
Roland Schweizer ◽  
David D. Martin ◽  
Stefan Ehehalt ◽  
Carl-Philipp Schwarze ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Prediction ◽  
Prediction Algorithms ◽  
Igf I ◽  
Short And Long Term

Efficacy of long-term growth hormone therapy in short non-growth hormone-deficient children

2017 ◽  
Vol 30 (2) ◽  
Author(s):  
Lucia Schena ◽  
Cristina Meazza ◽  
Sara Pagani ◽  
Valeria Paganelli ◽  
Elena Bozzola ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Final Height ◽  
Standard Deviation Score ◽  
Bone Age ◽  
Gh Treatment ◽  
Short Children ◽  
Igf I ◽  
Height Gain ◽  
The Cost

AbstractBackground:In recent years, several studies have been published showing different responses to growth hormone (GH) treatment in idiopathic short stature children. The aim of the present study was to investigate whether non-growth-hormone-deficient (non-GHD) short children could benefit from long-term GH treatment as GHD patients.Methods:We enrolled 22 prepubertal children and 22 age- and sex-matched GHD patients, with comparable height, body mass index (BMI), bone age, and insulin-like growth factor 1 (IGF-I) circulating levels. The patients were treated with recombinant human GH (rhGH) and followed until they reach adult height.Results:During GH treatment, the two groups grew in parallel, reaching the same final height-standard deviation score (SDS) and the same height gain. On the contrary, we found significantly lower IGF-I serum concentrations in non-GHD patients than in GHD ones, at the end of therapy (p=0.0055).Conclusions:In our study, the response to GH treatment in short non-GHD patients proved to be similar to that in GHD ones. However, a careful selection of short non-GHD children to be treated with GH would better justify the cost of long-term GH therapy.

Sign in / Sign up

Export Citation Format

Share Document